Shield Therapeutics plc
Status: Publicly traded
Direct answer
Shield Therapeutics plc is publicly traded on LSE under the ticker STX.L.
Shield Therapeutics plc is a specialized pharmaceutical firm dedicated to developing and commercializing innovative drugs at various clinical stages to address significant unmet medical requirements. Their flagship product, Accrufer/Feraccru, is an oral, non-salt-based treatment specifically designed for adult patients experiencing iron deficiency, with or without associated anemia. The company is also advancing...
Can you invest in Shield Therapeutics plc?
Yes. Shield Therapeutics plc trades publicly on LSE as STX.L.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Shield Therapeutics plc
Detailed equity research is provided by MarketSnap.